The CAIPIRINHA technique improved the image quality of hepatic arterial phase imaging with gadoxetic acid, reducing the number of non-diagnostic arterial phase studies.
I n cerebral ischemia due to large-vessel occlusion, cell viability depends on the collateral perfusion status (1,2). Infarction might be complete in less than 1 hour or may not be complete for hours or days depending on the collateral perfusion status, which varies among patients (3,4). Therefore, recanalization and reperfusion treatment can be futile or even dangerous when performed in the standard optimal time window, but could be useful if performed in a later time window (5)(6)(7)(8). Studies have shown that a large ischemic core combined with poor collaterals is a strong predictor of an unfavorable response to endovascular treatment and poor functional outcomes. Hence, the exclusion of patients with a large ischemic core and poor collateral circulation could prevent administration of futile and dangerous recanalization therapy. Conversely, good collateral circulation can limit ischemic core expansion and prolong the time the penumbral tissue at risk remains salvageable until reperfusion therapy. Some studies have suggested that the time window for endovascular treatment can be successfully extended in patients with good collaterals (9-14). These results demonstrate the importance of accurately estimating the collateral perfusion status to enable patientspecific application of treatment, thereby improving functional outcomes among patients with acute ischemic stroke due to large-vessel occlusion.Recently, researchers have developed dynamic collateral imaging methods such as multiphase CT angiography and collateral flow maps derived from dynamic susceptibility contrast material-enhanced perfusion MRI (15,16). Studies evaluating these collateral imaging approaches have shown that collateral status is a strong predictor of final infarct size and functional outcomes in patients considered eligible for intra-arterial thrombectomy and intravenous thrombolysis (17,18). For intra-arterial thrombectomy, it
ObjectivesGlucose metabolism, perfusion, and water diffusion may have a relationship or affect each other in the same tumor. The understanding of their relationship could expand the knowledge of tumor characteristics and contribute to the field of oncologic imaging. The purpose of this study was to evaluate the relationships between metabolism, vasculature and cellularity of advanced hepatocellular carcinoma (HCC), using multimodality imaging such as 18F-FDG positron emission tomography (PET), dynamic contrast enhanced (DCE)-MRI, and diffusion weighted imaging(DWI).Materials and MethodsTwenty-one patients with advanced HCC underwent 18F-FDG PET, DCE-MRI, and DWI before treatment. Maximum standard uptake values (SUVmax) from 18F-FDG-PET, variables of the volume transfer constant (Ktrans) from DCE-MRI and apparent diffusion coefficient (ADC) from DWI were obtained for the tumor and their relationships were examined by Spearman’s correlation analysis. The influence of portal vein thrombosis on SUVmax and variables of Ktrans and ADC was evaluated by Mann-Whitney test.ResultsSUVmax showed significant negative correlation with Ktrans
max (ρ = −0.622, p = 0.002). However, variables of ADC showed no relationship with variables of Ktrans or SUVmax (p>0.05). Whether portal vein thrombosis was present or not did not influence the SUV max and variables of ADC and Ktrans (p>0.05).ConclusionIn this study, SUV was shown to be correlated with Ktrans in advanced HCCs; the higher the glucose metabolism a tumor had, the lower the perfusion it had, which might help in guiding target therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.